Seven Fleet Capital Management LP Makes New Investment in Eupraxia Pharmaceuticals Inc. $EPRX

Seven Fleet Capital Management LP purchased a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the first quarter, Holdings Channel reports. The institutional investor purchased 709,515 shares of the company’s stock, valued at approximately $5,137,000. Eupraxia Pharmaceuticals comprises about 1.6% of Seven Fleet Capital Management LP’s portfolio, making the stock its 16th largest position.

Other large investors also recently made changes to their positions in the company. Vivo Capital LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter worth approximately $7,965,000. Affinity Asset Advisors LLC grew its position in Eupraxia Pharmaceuticals by 429.7% in the first quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after buying an additional 1,289,005 shares during the last quarter. Redmile Group LLC acquired a new position in Eupraxia Pharmaceuticals in the first quarter worth approximately $5,068,000. Rubric Capital Management LP bought a new position in shares of Eupraxia Pharmaceuticals in the first quarter valued at $5,004,000. Finally, Ikarian Capital LLC bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at $4,606,000.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, July 15th. Oppenheimer began coverage on Eupraxia Pharmaceuticals in a report on Thursday, June 25th. They set an “outperform” rating and a $17.00 target price for the company. Finally, Stifel Nicolaus assumed coverage on Eupraxia Pharmaceuticals in a research report on Thursday, May 21st. They issued a “buy” rating and a $25.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Eupraxia Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Eupraxia Pharmaceuticals Price Performance

Shares of EPRX opened at $6.40 on Friday. The company has a market capitalization of $416.13 million, a price-to-earnings ratio of -6.10 and a beta of 1.05. Eupraxia Pharmaceuticals Inc. has a fifty-two week low of $5.04 and a fifty-two week high of $9.32. The company has a debt-to-equity ratio of 0.02, a current ratio of 19.31 and a quick ratio of 19.31. The business’s 50-day moving average is $6.47 and its 200-day moving average is $7.29.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). Equities research analysts expect that Eupraxia Pharmaceuticals Inc. will post -0.88 EPS for the current fiscal year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.